Pharma IQ Glossary: Central Nervous System (CNS)
The Center For Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines. For example, fluoride toothpaste, antiperspirants, dandruff shampoos and sunscreens are all considered "drugs."
Update on Regulations Surrounding CNS in Europe: BfArM session on Optimising Clinical Development for CNS
January 11 by Pharma IQ NewsDr. Karl Broich, Vice President, BfArM, will discuss the new regulatory landscape as well as projected amendments to the current guidance documents on CNS clinical trials at Optimising Clinical...
Cutting Attrition Rates in Your CNS Clinical Trials
January 07 by Helen WinsorDr. Wolfgang Eglmeier, Head of Clinical Operations Germany, Grünenthal GmbH, joins Helen Winsor from Pharma IQ, to discuss optimising clinical development in CNS. He outlines the main challenges when...
Market for CNS Biomarkers Predicted to Grow to $3.2 Billion by 2015
December 02 by Pharma IQBiomarkers are now being used by a large number of companies in the biopharmaceutical industry - and one of the key therapeutic areas where they are utilised is in CNS drug development, wher...
